| Literature DB >> 24098554 |
Claudia Siegl1, Patricia Hamminger, Herbert Jank, Uwe Ahting, Benedikt Bader, Adrian Danek, Allison Gregory, Monika Hartig, Susan Hayflick, Andreas Hermann, Holger Prokisch, Esther M Sammler, Zuhal Yapici, Rainer Prohaska, Ulrich Salzer.
Abstract
Neuroacanthocytosis (NA) refers to a group of heterogenous, rare genetic disorders, namely chorea acanthocytosis (ChAc), McLeod syndrome (MLS), Huntington's disease-like 2 (HDL2) and pantothenate kinase associated neurodegeneration (PKAN), that mainly affect the basal ganglia and are associated with similar neurological symptoms. PKAN is also assigned to a group of rare neurodegenerative diseases, known as NBIA (neurodegeneration with brain iron accumulation), associated with iron accumulation in the basal ganglia and progressive movement disorder. Acanthocytosis, the occurrence of misshaped erythrocytes with thorny protrusions, is frequently observed in ChAc and MLS patients but less prevalent in PKAN (about 10%) and HDL2 patients. The pathological factors that lead to the formation of the acanthocytic red blood cell shape are currently unknown. The aim of this study was to determine whether NA/NBIA acanthocytes differ in their functionality from normal erythrocytes. Several flow-cytometry-based assays were applied to test the physiological responses of the plasma membrane, namely drug-induced endocytosis, phosphatidylserine exposure and calcium uptake upon treatment with lysophosphatidic acid. ChAc red cell samples clearly showed a reduced response in drug-induced endovesiculation, lysophosphatidic acid-induced phosphatidylserine exposure, and calcium uptake. Impaired responses were also observed in acanthocyte-positive NBIA (PKAN) red cells but not in patient cells without shape abnormalities. These data suggest an "acanthocytic state" of the red cell where alterations in functional and interdependent membrane properties arise together with an acanthocytic cell shape. Further elucidation of the aberrant molecular mechanisms that cause this acanthocytic state may possibly help to evaluate the pathological pathways leading to neurodegeneration.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24098554 PMCID: PMC3789665 DOI: 10.1371/journal.pone.0076715
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Blood samples of patients, acanthocyte count and clinical information.
| sample | sex | age | origin | acanthocytes | acanthocytes in control | molecular findings | mutations found | prominent clinical features |
|---|---|---|---|---|---|---|---|---|
| ChAc1 | ♀ | 33 | DE | 39,8% | 20,2% | chorein missing | VPS13A, c.4282GC; c.7806GA, | chorea, epilepsy, tongue dystonia, dysarthria |
| ChAc2 | ♀ | 40 | GB | 21,1% | 1,3% | chorein missing | VPS13A, 1208delAGAC; 7867C>T | chorea, epilepsy, tongue dystonia, dysphagia, dysarthria |
| ChAc3 | ♂ | 46 | DE | 24,8% | 6,6% | chorein missing | VPS13A, c.8529_8530het_dupA; c.9078-2A>G, | epilepsy, dysarthria, symmetric parkinson syndrome, cognitive impairment |
| ChAc4 | ♂ | 48 | GB | 25,6% | 11,1% | chorein missing | VPS13A, 237delT; 9429delAGAG | chorea, epilepsy, tongue biting, dysarthria |
| ChAc5 | ♀ | 39 | GB | 45,9% | 3,1% | chorein missing | n/a | chorea, dysarthria |
| ChAc6 | ♂ | 26 | DE | 26,7% | 7,0% | chorein missing | VPS13A, c.6059 delC, second mutation n/a | chorea, epilepsy |
| ChAc7 | ♂ | 21 | DE | 25,8% | 11,3% | chorein missing | VPS13A, c.6059 delC, second mutation n/a | epilepsy |
| ChAc8 | ♀ | 43 | DE | 19,4% | 10,4% | chorein missing | n/a | chorea, epilepsy, dysarthria, cognitive impairment |
| ChAc9 | ♂ | 53 | GB | 12,5% | 3,6% | chorein missing | n/a | chorea |
| ChAc10 | ♀ | 47 | ES | 1,5% | 3,5% | n/a | VPS13A, exon 54 deletion, homozygous | n/a |
| ChAc11 | ♂ | 45 | ES | 40,0% | 3,5% | n/a | VPS13A, exon 54 deletion, homozygous | n/a |
| ChAc12 | ♂ | 38 | ES | 49,0% | 3,5% | n/a | VPS13A, exon 54 deletion, homozygous | n/a |
| MLS1 | ♂ | 63 | GB | 33,3% | 2,1% | Kx missing | XK, c. 1023G>A | profound orofacial dyskinesia, dysphagia, dysarthria, severe sensorimotor neuropathy with generalized muscle wasting, bedbound, pituitary macroadenoma on MR imaging, CK aemia. |
| PKAN+1 | ♂ | 7 | DE | 29,2% | 0,7% | n/a | PANK2, c.1561GA p.G521R, second mutation n/a | n/a |
| PKAN+2 | ♂ | 12 | TR | 22,1% | 1,5% | n/a | PANK2, c.628+2TG, homozygous | * generalized dystonia, bilateral mild rigidity, mild pyramidal signs, no walking since age 8 |
| PKAN+3 | ♀ | 8 | TR | 42,3% | 1,8% | n/a | PANK2, c.664CT, homozygous | * generalized dystonic and pyramidal signs prominent in lower limbs |
| PKAN+4 | ♂ | 15 | TR | 33,1% | 2,3% | n/a | PANK2, c.664CT, homozygous | * generalized dystonic and pyramidal signs in the lower extremities |
| PKAN+5 | ♂ | 7 | USA | 17,5% | 4,6% | n/a | PANK2, c.215insA, homozygous | n/a |
| PKAN+6 | ♂ | 9 | TR | 41,1% | 12,8% | n/a | PANK2, c.1325_1328ATAG homozygous | * oromandibular and axial dystonia from age 7 |
| MPAN-1 | ♀ | 14 | TR | 3,4% | 6,0% | n/a | c19orf12, c.194GA p. G65E, homozygous | * dystonic movements in extremities, prominent in the limbs, pyramidal and cerebellar signs |
| PKAN-2 | ♂ | 33 | TR | 3,7% | 6,5% | n/a | PANK2, c.1466TC; 1583C>T | very severe generalized dystonia, some pyramidal signs |
| PKAN-3 | ♀ | 27 | USA | 1,0% | 2,9% | n/a | PANK2, c.1231GA; c.1255AG | n/a |
| PKAN-4 | ♂ | 25 | USA | 0,0% | 3,2% | n/a | PANK2, c.1231GA; c.1255AG | n/a |
| PKAN-5 | ♀ | 25 | USA | 2,4% | 1,9% | n/a | PANK2, c.987del; c.1253CT | n/a |
| PKAN-6 | ♀ | 17 | USA | 1,4% | 2,6% | n/a | PANK2 (details n/a) | n/a |
Patient characteristics and acanthocyte count in patient samples and their respective controls. Results of molecular and/or genetic analysis as well as clinical findings in the patients are given where available.
ChAc: Chorea Acanthocytosis, MLS: McLeod Syndrome. PKAN+: panthotenate kinase-associated neurodegeneration with acanthocytosis. PKAN- panthotenate kinase-associated neurodegeneration without acanthocytes. MPAN-1: mitochondrial membrane protein-associated neurodegeneration diagnosed patient, counted to the PKAN- group because of the lack of acanthocytes. Age of the patient at the time of blood sampling and code for country of sample origin are given. Findings from molecular and/or genetic diagnosis and clinical presentation of the patients are given. * denotes offspring of consanguinity marriage. n/a means detailed information is not available.
Please, note that patients ChAc6 and Chac7 are siblings, as are patients ChAc10-12 as well as patients PKAN+3 and PKAN+4 and patients PKAN-3 and PKAN-4.
Patients ChAc1 and ChAc2 correspond to patients 1 and 2, respectively, of Bader et al. [44]. ChAc4 is patient 4 of Dobson-Stone et al. [45]. ChAc6 and ChAc7 are patients 2 and 1, respectively, of Scheid et al. [46]. ChAc10-12 will be described in Velayos-Baeza et al. (manuscript in preparation).
Figure 1Microscopic comparison of patient’s and control erythrocytes in drug-induced endovesiculation.
Erythrocytes of a PKAN+ patient (B and D) and a control donor (A and C) were treated with 3 mM primaquine (A and B) or 0.8 mM chlorpromazine (C and D) in the presence of FITC-dextran to monitor the formation of endovesicles by confocal microscopy. Representative phase contrast (left panels), fluorescence (middle panels) and overlay (right panels) images are shown.
Figure 2Dose-dependent uptake of fluid phase FITC-dextran by erythrocytes treated with amphiphilic drugs.
Erythrocytes were suspended in FITC-labeled dextran and incubated with the indicated amphiphilic drugs to induce endovesiculation. Upon washing, the uptake of fluorescent label was quantified by flow cytometry. Representative histograms are shown. The concentrations were 1.5, 0.4 and 0.375 mM (blue) and 3.0, 0.6 and 0.75 mM (green) for primaquine, chlorpromazine and imipramine, respectively (red is a control incubation without drug).
Figure 3Altered drug-induced endovesiculation of erythrocytes from neuroacanthocytosis patients.
ChAc, McLeod and PKAN+, as well as control erythrocytes were subjected to drug-induced endovesiculation using 1.5 mM primaquine, 0.4 mM chlorpromazine and 0.75 mM imipramine. The uptake of FITC-labeled dextran was determined by flow cytometry. Overlays of representative histograms of patients (red) and respective control samples (blue) clearly indicate an impaired ability of the patient’s erythrocytes to form endovesicles.
Figure 4Impaired drug-induced endovesiculation in erythrocytes of patients with acanthocytosis.
Erythrocytes from patients (ChAc, PKAN+, PKAN-) and control donors were subjected to drug-induced endovesiculation using 3 mM primaquine. The amount of FITC-dextran positive cells (in %) was assessed by flow cytometry as described. Respective pairs of patient and control donors are connected by lines. The data of the MPAN patient within the NBIA/PKAN- cohort is shown as a dashed line.
Figure 5Inverse correlation between drug-induced endovesiculation and erythrocyte shape.
The amount of FITC-dextran positive cells upon primaquine-induced endovesiculation (collective data from Figure 4) is blotted against the percent of acanthocytes in the blood sample. ChAc patients (circles), PKAN+ patients (rectangles), PKAN- patients (crosses) and all control samples (triangles) are indicated. A linear regression line is shown (R2 = 0.501). Negative correlation between the ability of erythrocytes to form drug-induced endovesicles and the amount of acanthocytes is observed with Pearson’s r being -0.707 and a 2-tailed significance of 0.01.
Figure 6Differences in LPA-induced PS exposure and calcium uptake in erythrocytes of neuroacanthocytosis patients.
Erythrocytes from ChAc, PKAN+ and PKAN- patients and control donors were treated with LPA as described in Materials and Methods and stained for PS exposure with FITC-annexin V (upper panels) or calcium uptake with Fluo-3 (lower panels) and analysed by flow cytometry. Overlays of representative histograms of patients (red) and controls (blue) show reduced PS exposure and calcium uptake in both ChAc and PKAN+ samples. The PKAN- sample does not differ from the respective control.
Figure 7Altered LPA-induced PS exposure and calcium uptake in erythrocytes of patients with acanthocytes.
Erythrocytes from patients and control donors were treated with LPA as described in Materials and Methods and either PS exposure (A) or calcium uptake (B) was monitored by flow cytometry. The percentage of FITC-annexin V-positive cells (A) and of Fluo-3-positive cells (B) of patient and control samples are shown and respective pairs are connected by lines. The data of the MPAN patient within the NBIA/PKAN- cohort is shown as a dashed line.
Figure 8Correlations between drug-induced endovesiculation, LPA-induced PS exposure and calcium uptake.
The data of ChAc patients (circles) and respective control samples (triangles) for % of cells with endovesicles upon incubation with primaquine, for % annexin V-positive cells and % Fluo-3-positive cells upon LPA treatment are blotted against each other as indicated (data derived from Figures 4 and 7). Linear regression lines are shown with R2 (shown as inserts). In each combination a positive correlation is observed with Pearson’s r and the 2-tailed significance (given as inserts).